key: cord-1027750-6e8iwrnw
authors: Li, Yayun; Deng, Yuhao; Ye, Lin; Sun, Huiyan; Du, Songtao; Huang, Huining; Zeng, Furong; Chen, Xiang; Deng, Guangtong
title: Clinical Significance of Plasma D-Dimer in COVID-19 Mortality
date: 2021-05-25
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.638097
sha: ff21a03bca934b1322a48808f6606b1e18014795
doc_id: 1027750
cord_uid: 6e8iwrnw

It is not clear whether D-dimer can be an independent predictor of coronavirus disease 2019 (COVID-19) mortality, and the cut-off of D-dimer for clinical use remains to be determined. Therefore, a comprehensive analysis is still necessary to illuminate the clinical significance of plasma D-dimer in COVID-19 mortality. We searched PubMed, Embase, Cochrane Library, and Scopus databases until November 2020. STATA software was used for all the statistical analyses. The identifier of systematic review registration was PROSPERO CRD42020220927. A total of 66 studies involving 40,614 COVID-19 patients were included in our meta-analysis. Pooled data showed that patients in high D-dimer group had poor prognosis than those in low D-dimer group [OR = 4.52, 95% CI = (3.61, 5.67), P < 0.001; HR = 2.81, 95% CI = (1.85, 4.27), P < 0.001]. Sensitivity analysis, pooled data based on different effect models and the Duval and Tweedie trim-and-fill method did not change the conclusions. Subgroup analyses stratified by different countries, cutoffs, sample size, study design, and analysis of OR/HR still keep consistent conclusions. D-dimer was identified as an independent predictor for COVID-19 mortality. A series of values including 0.5 μg/ml, 1 μg/ml, and 2 μg/ml could be determined as cutoff of D-dimer for clinic use. Measurement and monitoring of D-dimer might assist clinicians to take immediate medical actions and predict the prognosis of COVID-19.

The outbreak and spread of Coronavirus Disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused a pandemic around the world (1) . Though most of patients had mild symptoms, a small minority of cases suffered from acute respiratory distress syndrome (ARDS) and even death (2) . As of November 28, 2020, about 60 million cases have been reported by world health organization (WHO) and included around 1.5 million deaths globally (1) . Worse still, the numbers of death are persistently increasing especially in the United States, the epicenter of COVID-19 (3) . Therefore, identification of the independent predictors for COVID-19 mortality is still urgent and necessary to reduce the poor outcomes.

D-dimer, a fibrinogen degradation product, consists of two covalently bound fibrin D domains, which reflect the high coagulation and enhancement of secondary fibrinolytic activity in vivo (4, 5) . Previous studies demonstrated that D-dimer was associated with the severity of COVID-19 (6) (7) (8) .

Hyperinflammation and hypoxia-induced injury caused by SARS-CoV-2 infection could cause the dysfunction of endothelial cells and stimulate thrombosis and elevation of D-dimer (9) . Elevated D-dimer could cause the formation of pulmonary microthrombus, deep venous thrombosis, and disseminated intravascular coagulopathy, which were associated with the poor prognosis (10) (11) (12) . Nowadays, increasing studies showed that Ddimer could be used as a predictor for COVID-19 mortality (9, 13) . Moreover, numerous review and meta-analyses highlighted the prognostic value of D-dimer in COVID-19 mortality (14) (15) (16) . However, one of the drawbacks of these analyses was that more attention was paid to D-dimer levels between survivors and nonsurvivors (17, 18) . Actually, the abnormal elevation of D-dimer was more valuable to reflect hemodynamic changes in clinic. In addition, these meta-analyses were based primarily on the studies using univariate analysis, and it was not clear whether D-dimers play an independent role in predicting COVID-19 mortality on admission (14, 19) . Another challenge is that the cutoff of Ddimer for clinical use remains to be determined (8) . From the above, a comprehensive analysis of all the published studies is still necessary to illuminate the clinical significance of plasma D-dimer in COVID-19 mortality.

To our knowledge, this is the largest meta-analysis about the association between D-dimer with COVID-19 mortality. Our study will determine its cutoff and highlight the independent prognostic value of D-dimer in COVID-19 mortality to assist clinicians to take immediate medical actions and evaluate the prognosis of COVID-19.

Our meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The following databases were searched: PubMed, Embase, Cochrane Library, and Scopus databases, from their inception to November 2020. No language restrictions were applied. The search terms were as follows: ("Coronavirus disease 2019" OR "Coronavirus 2019" OR "COVID-19" OR "COVID19" OR "Severe acute respiratory syndrome coronavirus 2" OR "SARS-CoV-2" OR "nCoV-2019" OR "2019-nCoV" OR "Novel coronavirus") AND ("Mortality" OR "Death" OR "Dead" OR "Fatality" OR "Non-survival" OR "Non-survivors" OR "Non-survivor" OR "Prognosis" OR "Deceased") AND ("D-dimer" OR "Laboratory"). Three of the authors (GD, FZ, and YL) independently screened initial records, titles, abstracts, and full text articles. Disagreements were resolved by discussion. In order to avoid missing relevant articles, we also manually reviewed the reference lists of selected retrieved papers as well as the major reviews and metaanalyses. The identifier of systematic review registration was PROSPERO CRD42020220927.

Any study reporting the relationship between D-dimer and COVID-19 mortality should be included if they met the following criteria: (1) patients were diagnosed as COVID-19;

(2) dichotomous D-dimer was available to evaluate the risk of COVID-19 mortality; or (3) odds ratio (OR) or hazard ratio (HR) of the D-dimer was accessible or estimated by the provided data or Kaplan-Meier curves based on the method previously described (20, 21). Exclusion criteria were as follows:

(1) patients were asymptomatic carriers of SARS-CoV-2; (2) studies with smaller sample size from the same authors or institutions; and (3) patients or studies did not fulfill the inclusion criteria.

We used Endnote X9 to exclude any duplicate and irrelevant studies in our initial search. We extracted the following basic information: first authors, publication date, country of origin, study design, cases, age, sex, cutoff of D-dimer, OR, HR, and its associated 95% confidence intervals (CI). OR and HR were extracted preferentially from multivariable analysis based on lower cutoff of D-dimer. Stratified data or interquartile range such as age were converted to mean (standard deviation) based on the mathematical formulas for meta-analysis (22, 23) . We used Newcastle-Ottawa Scale (NOS) for quality assessments. Two authors (GD and FZ) independently selected and evaluated the included articles. When a consensus was lacking, a third reviewer (LY) was consulted to solve the disagreements.

STATA (Version 12.0; STATA Corporation, College Station, TX, USA) and TSA (Copenhagen trial unit) software were used for all the statistical analyses. OR with 95% CI was calculated for binary outcomes, and HR for time-to-event outcomes (24) . Random-effect and fixed-effect models were both adopted in all analyses to assess the stability of results. Additionally, sensitivity analyses were performed by omitting one study each time; meta-regression and subgroup analyses were conducted based on different countries, cutoffs, sample size, study design, and analysis of OR/HR to further evaluate the consistency of our conclusions. The funnel plot and Egger test was used to evaluate publication bias, and the Duval and Tweedie trim-and-fill method was performed to adjust for this bias (25) . Trial sequential analysis was used to eliminate early false positive findings. P < 0.05 was considered statistically significant.

We initially identified 4,372 records through our search strategy and scanning the reference lists of related meta-analyses ( Figure 1) ; 3,571 studies remained after excluding duplicates. Then we reviewed the titles and abstracts and obtained 678 studies for full-text scanning. We further excluded 612 studies due to studies without our concerned outcomes (n = 371), studies without dichotomous D-dimer (n = 128), review and metaanalyses (n = 55) and other reasons including duplicates, letters, and comments (n = 12). Finally, a total of 66 studies involving 40,614 COVID-19 patients were included in our meta-analysis (9, 13, .

The main characteristics of eligible studies are shown in 

Fifty-six studies reported the proportion of non-survivors between high and low D-dimer groups. With heterogeneity (I 2 = 79.6%, P < 0.001), the random-effect model was performed and suggested that patients in the high D-dimer group had higher proportion of mortality than those in the low D-dimer group [OR = 4.52, 95% CI = (3.61, 5.67), P < 0.001]. The conclusion did not change when using the fixed-effect model for meta-analysis [OR = 3.28, 95% CI = (3.00, 3.58), P < 0.001] (Figure 2 ). Sensitivity analysis did not change the conclusion (Supplementary Figure 1) . The funnel plot was not in a form of symmetry, indicating the existence of potential publication bias (Supplementary Figure 2A) . Then we used Egger test to detect the presence of publication bias (P < 0.001) (Supplementary Figure 2B) . However, the conclusion did not change in fixed-effect model [OR = 2.92, 95% CI = (2.68, 3.18), P < 0.001] or random-effect model [OR = 3.33, 95% CI = (2.66, 4.16), P < 0.001] after filling 15 studies in the comparison. To examine whether the observed heterogeneity could be contributed by possible moderators, univariate metaregression was performed and suggested that country and analysis of OR were possible significant moderators ( Table 2) . To further assess the stability of the conclusion, we conducted the subgroup analysis stratified by different countries, cutoffs, sample size, study design, and analysis of OR. The conclusion did not change, highlighting the independent prognostic value of D-dimer and that the cutoff of D-dimer could be determined as a series of values including 0.5 µg/ml, 1 µg/ ml, and 2 µg/ ml (Figure 3) .

Fifteen studies reported HRs of high D-dimer vs. low Ddimer. Due to the heterogeneity among studies (I 2 = 83.7%, (Figure 4) . We further performed a sensitivity analysis through excluding any one specific study each time. We did not observe obvious decline of heterogeneity, and the conclusion was consistent (Supplementary Figure 3A) . The funnel plot identified four studies over the pseudo 95% CI (Supplementary Figure 3B) , and the Egger test detected the presence of publication bias (P = 0.013) (Supplementary Figure 3C) . Then the Duval and Tweedie trim-and-fill method was adopted, but no studies were trimmed and filled. To explore the origin of heterogeneity, we performed the univariate meta-regression and found that analysis of HR was possible significant moderator ( Table 3 ). Subgroup analysis based on different countries, cutoffs, sample size, study design, and analysis of HR did not change the conclusion, which means D-dimer is an independent indicator for COVID-19 mortality, and the cutoff of D-dimer (0.5µg/ ml or 1µg/ ml) could be used clinically ( Figure 5 ).

Trial sequential analysis has been widely used to improve the reliability of conclusion and eliminate early false positive findings due to imprecision and repeated significance testing in metaanalyses (90) . We collected the numbers of death and total numbers of patients in the high and low D-dimer group from 37 studies (Supplementary Table 2) . Trial sequential analysis on data for death supported a 20% risk ratio reduction in the low Ddimer group compared with high D-dimer group. The required information size of 42,893 was calculated based on a control event proportion of 11.5% (based on data in our meta-analysis), a risk of type I error of 5%, a power of 80%, and a diversity of 87.16%. Although the actual information size did not reach the required Frontiers in Medicine | www.frontiersin.org information size, the cumulated Z-curve (blue curve) crossed the traditional boundary of 5% significance (horizontal red line) and the trial sequential monitoring boundary (red curve), implying that firm evidence was reached (Figure 6 ).

The ongoing spread of COVID-19 is posing a huge threat to global public health. Nowadays, the numbers of deaths caused by COVID-19 are still increasing while there is still no effective medication (64) . Thus, it's imperative to identify the predictors for COVID-19 mortality. With regard to the role of plasma Ddimer in COVID-19 mortality, studies have reported associations that vary in strength and direction. Therefore, a comprehensive meta-analysis is necessary to illuminate the clinical significance of plasma D-dimer in COVID-19 mortality.

In this meta-analysis, a total of 66 studies involving 40,614 COVID-19 patients were enrolled. We found that patients in high D-dimer group had a poorer prognosis than those in low D-dimer group, independent of countries, cutoffs, sample size, study design, and analysis of OR/HR. Sensitivity analysis and pooled data based on different effect models were used to explore the consistency of our conclusions, and the conclusions were still consistent. Additionally, even though there exist publication bias in the combined outcomes of high D-dimer vs. low Ddimer, the conclusion still did not change after the Duval and Tweedie trim-and-fill method. Trial sequential analysis further confirmed our conclusions. Based on the above findings, we could conclude that D-dimer was an independent predictor for COVID-19 mortality. Furthermore, subgroup analyses based on cutoffs of dimer highlighted that a series of values including 0.5 µg/ ml, 1 µg/ ml, and 2 µg/ ml could be determined as the cutoff of D-dimer for clinic use.

D-dimer is one of the commonest laboratory findings for COVID-19 patients. As early as February 2019, Guan et al. reported that severe patients had a significantly higher level of Ddimer than non-severe patients through analyzing 1,099 patients with laboratory-confirmed COVID-19 from over 550 hospitals in China (91) . Moreover, Zhou and his colleague conducted a retrospective study involving 191 COVID-19 patients and found that elevated D-dimer at admission was a risk factor for death of adult patients (13) . However, this conclusion was not consistent in other studies. Xie et al. found that D-dimer is not a risk factor after adjustment of age and gender through analyzing 140 COVID-19 patients (79) . Besides, Liu and his team even did not find the difference in the unadjusted association between D-dimer and all-cause death in COVID-19 patients (35) . Therefore, our findings are necessary to solve the problem and highlight the clinical significance of plasma D-dimer in COVID-19 mortality.

The mechanism is still unknown about the association between elevated D-dimer with COVID-19 mortality. Wang et al. previously showed that the significantly increased D-dimer and corresponding hypoxemia could induce the formation of pulmonary microthrombus in the 2009 novel influenza A(H1N1) (10) . A recent study conducted by Klok and his colleague demonstrated that approximately 31% COVID-19 patients in intensive care unit had the thrombotic complications (11) . Moreover, D-dimer could be used to indicate deep venous thrombosis in COVID-19 patients with cardiovascular diseases (92) . That means elevated level of D-dimer, the indicator of thrombotic complications, might be the cause of COVID-19 mortality. However, other studies held different opinions that COVID-19 progress is the cause of the increase of D-dimer level. One possible mechanism is that SARS-CoV-2 infections are usually accompanied by an aggressive inflammatory response and even cytokine storm. The hyperinflammation could induce the dysfunction and damage of endothelial cells, resulting in the elevation of D-dimer and excess thrombin generation (93) . Additionally, organ damage and corresponding hypoxemia caused by SARS-CoV-2 infection could stimulate thrombosis through increasing blood viscosity and activating hypoxiainducible transcription factor-dependent signaling pathways (94, 95) . Recently, Turagam et al. found that mortality is mostly associated with pulseless electrical activity. Whether D-dimerassociated thrombosis could cause pulseless electrical activity and ultimately mortality needs to be clarified (96) . Overall, The underlying mechanism is unsolved about the relationship between elevated D-dimer and COVID-19 mortality. Our finding highlights the association, and more studies are needed to dig out the detailed mechanism.

To our knowledge, this is the largest meta-analysis to evaluate the clinical significance of plasma D-dimer in COVID-19 mortality. However, several limitations must be acknowledged. First, noticeable heterogeneity exists in all of the analyses. Sensitivity analysis pooled the data based on different effect models, yet the heterogeneity could not be eliminated completely. Second, publication bias exists in all the comparisons, though the conclusion did not change through the Duval and Tweedie trimand-fill method. Finally, our study could not clarify the underlying mechanism between D-dimer with COVID-19 mortality.

In conclusion, D-dimer was identified as an independent predictor for COVID-19 mortality. A series of values including 0.5 µg/ ml, 1 µg/ ml, and 2 µg/ ml could be determined as cutoff of D-dimer for clinic use. Measurement and monitoring of Ddimer might assist clinicians to take immediate medical actions and predict the prognosis of COVID-19.

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

YL and YD: data curation, formal analysis, methodology, roles/writing-original draft. LY: conceptualization, data curation, formal analysis, methodology, roles/writing-original draft. HS: formal analysis, methodology, roles/writing-revised draft. SD and HH: methodology, software, validation. FZ, GD, and XC: conceptualization, data curation, formal analysis, software, supervision, validation, visualization, roles/writing-original draft, writing-review & editing. All authors contributed to the article and approved the submitted version. Supplementary Table 1 | Methodological quality of studies included in the meta-analysis.

Supplementary Table 2 | Raw data for all the analyses in the study.

Virtual Press Conference on COVID-19

Suppressed T cellmediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan

Preparation in the big apple: New York City, a new epicenter of the COVID-19 pandemic

Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: a meta-analysis

Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation

D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis

Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score

Elevated Ddimer levels on admission are associated with severity and increased risk of mortality in COVID-19: a systematic review and meta-analysis

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Serum Ddimer changes and prognostic implication in

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis

Characteristics of mortal COVID-19 cases compared to the survivors

D-Dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: a meta-analysis

D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients

Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: A meta-analysis

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Practical methods for incorporating summary time-to-event data into meta-analysis

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Laparoscopic versus open gastrectomy for gastric cancer

Can we predict the severity of coronavirus disease 2019 with a routine blood test?

A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity

The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort

Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort

Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease

Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

Prevalence and outcomes of d-dimer elevation in hospitalized patients with COVID-19

Risk factors for in-hospital mortality from COVID-19 infection among black patients-an urban center experience

Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China

Clinical Characteristics and outcomes of older patients with coronavirus disease 2019 (Covid-19) in Wuhan, China: a single-centered, retrospective study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19

Laboratory markers associated with COVID-19 progression in patients with or without comorbidity: a retrospective study

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

Predictors of mortality in adults admitted with COVID-19: Retrospective cohort study from New York City

Risk factors for mortality among hospitalized patients with COVID-19. An overview in Mexican population

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

COVID-19 with different severities: a multicenter study of clinical features

30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study

Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: a retrospective observational study

A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19

IL-6-based mortality risk model for hospitalized patients with COVID-19

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19

Predictors of fatality including radiographic findings in adults with COVID-19

Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19

Analysis of the risk factors for mortality in adult covid-19 patients in Wuhan: a multicenter study

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

Clinical predictors of COVID-19 disease progression and death: analysis of 214 hospitalized patients from Wuhan, China

Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

Clinical characteristics and outcomes of adult critically ill patients with COVID-19 in Honghu

Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China. medRxiv

Characteristic of 523 COVID-19 in Henan Province and a Death Prediction Model. Front Public Health

Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: derivation and validation of the HA2T2 COVID-19 mortality risk score

Risk factors for mortality in patients with COVID-19 in New York City

Anticoagulation and bleeding risk in patients with COVID-19

Factors associated with death outcome in patients with severe coronavirus disease-19 (Covid-19): a case-control study

Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. medRxiv

Clinical features of critically ill patients infected with SARS-CoV-2 outside Wuhan with and without diabetes

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Impaired immune and coagulation systems may be early risk factors for COVID-19 patients: a retrospective study of 118 inpatients from Wuhan

Coagulation parameters: an efficient measure for predicting the prognosis and clinical management of patients with COVID-19

High sensitivity troponin-T for prediction of adverse events in patients with COVID-19

Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: a multicenter study

Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan

Elective tracheostomy during COVID-19 outbreak: to whom, when, how? Early experience from Venice, Italy

15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study

Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Clinicopathological features and outcomes of acute kidney injury in critically ill COVID-19 with prolonged disease course: a retrospective cohort

Association between hypoxemia and mortality in patients with COVID-19

Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study

Myocardial injury and risk factors for mortality in patients with COVID-19 pneumonia

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Clinical characteristics, associated factors, and predicting covid-19 mortality risk: a retrospective study in Wuhan, China

Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients

Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study

Clinical features predicting mortality risk in older patients with COVID-19

Risk factors for mortality in 220 patients with COVID-19 in Wuhan, China: a singlecenter, retrospective study

User Manual for Trial Sequential Analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Dynamic relationship between D-dimer and COVID-19 severity

Coagulation and sepsis

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The stimulation of thrombosis by hypoxia

Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2021 Li, Deng, Ye, Sun, Du, Huang, Zeng, Chen and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.